AACE ePoster Library

THE IMPACT OF GASTROINTESTINAL ADVERSE EVENTS ON WEIGHT LOSS WITH LIRAGLUTIDE 3.0 MG AS ADJUNCT TO A DIET AND EXERCISE PROGRAM
AACE ePoster Library. Lean M. 05/13/15; 97768; 611
Michael Lean
Michael Lean
Login now to access Regular content available to all registered users.
Abstract
Rate & Comment (0)
Objective: To explore any associations between gastrointestinal adverse events (GI AEs) and weight loss with liraglutide 3.0 mg/day in addition to a diet and exercise program in individuals without type 2 diabetes who were obese (BMI ≥30 kg/m2) or overweight (BMI 27–29.9 kg/m2) with at least one comorbidity.
Methods: The SCALE Obesity and Prediabetes trial was a randomized, double-blind, multi-center trial in which individuals (mean age 45.1 years, 78.5% female, mean weight 106.2 kg, mean BMI 38.3 kg/m2, 61% with prediabetes) were enrolled in a long-term weight management program and randomized to liraglutide 3.0 mg (n=2487) or placebo (n=1244). These data are from an exploratory analysis based on groups of individuals defined by occurrence of GI AEs (0–16 weeks, 0–56 weeks). Weight loss at week 56 is presented as least squares means using LOCF, with p-values denoting whether or not GI AEs had a significant effect on treatment.
Results: Overall, liraglutide 3.0 mg was associated with a greater weight loss from baseline than placebo (8.0% vs. 2.6%, respectively, p<0.0001). As expected, more individuals on liraglutide 3.0 mg (68.3%) compared with placebo (40.3%) reported GI AEs; the most prevalent GI AEs were nausea (40.2 vs. 14.7%), diarrhea (20.9 vs. 9.3%), constipation (20.0 vs. 8.7%) and vomiting (16.3 vs. 4.1%), occurring mostly within the first 16 weeks of treatment. There was no significant difference in weight loss between individuals who did or did not experience ≥1 episode of nausea/vomiting during 0–56 weeks, regardless of treatment (liraglutide 3.0 mg: nausea/vomiting, -7.8%, no nausea/vomiting, -8.1%; placebo: nausea/vomiting -2.5%, no nausea/vomiting -2.6%, p=0.81). Similar results were seen if all other types of GI AE combined were included. Moreover, no significant differences were observed at week 56 for weight loss in individuals who experienced 0, 1, 2-3, or ≥4 GI AEs in the first 16 weeks (7.7–8.2% with liraglutide 3.0 mg vs. 2.3–3.0% with placebo, p=0.24), or during the entire 56 weeks of treatment (7.7–8.4% with liraglutide 3.0 mg vs. 2.4-3.2% with placebo, p=0.55). Although those experiencing 0 GI AEs appeared to perform slightly better than the other groups, this may be explained by the higher withdrawal rate as the number of GI AE increase. These results were further supported by comparable mean weight loss profiles over time across the 0, 1, 2-3, or ≥4 GI AE groups.
Conclusion: The weight loss observed with liraglutide 3.0 mg is not explained by the occurrence of GI AEs, including nausea/vomiting.
Objective: To explore any associations between gastrointestinal adverse events (GI AEs) and weight loss with liraglutide 3.0 mg/day in addition to a diet and exercise program in individuals without type 2 diabetes who were obese (BMI ≥30 kg/m2) or overweight (BMI 27–29.9 kg/m2) with at least one comorbidity.
Methods: The SCALE Obesity and Prediabetes trial was a randomized, double-blind, multi-center trial in which individuals (mean age 45.1 years, 78.5% female, mean weight 106.2 kg, mean BMI 38.3 kg/m2, 61% with prediabetes) were enrolled in a long-term weight management program and randomized to liraglutide 3.0 mg (n=2487) or placebo (n=1244). These data are from an exploratory analysis based on groups of individuals defined by occurrence of GI AEs (0–16 weeks, 0–56 weeks). Weight loss at week 56 is presented as least squares means using LOCF, with p-values denoting whether or not GI AEs had a significant effect on treatment.
Results: Overall, liraglutide 3.0 mg was associated with a greater weight loss from baseline than placebo (8.0% vs. 2.6%, respectively, p<0.0001). As expected, more individuals on liraglutide 3.0 mg (68.3%) compared with placebo (40.3%) reported GI AEs; the most prevalent GI AEs were nausea (40.2 vs. 14.7%), diarrhea (20.9 vs. 9.3%), constipation (20.0 vs. 8.7%) and vomiting (16.3 vs. 4.1%), occurring mostly within the first 16 weeks of treatment. There was no significant difference in weight loss between individuals who did or did not experience ≥1 episode of nausea/vomiting during 0–56 weeks, regardless of treatment (liraglutide 3.0 mg: nausea/vomiting, -7.8%, no nausea/vomiting, -8.1%; placebo: nausea/vomiting -2.5%, no nausea/vomiting -2.6%, p=0.81). Similar results were seen if all other types of GI AE combined were included. Moreover, no significant differences were observed at week 56 for weight loss in individuals who experienced 0, 1, 2-3, or ≥4 GI AEs in the first 16 weeks (7.7–8.2% with liraglutide 3.0 mg vs. 2.3–3.0% with placebo, p=0.24), or during the entire 56 weeks of treatment (7.7–8.4% with liraglutide 3.0 mg vs. 2.4-3.2% with placebo, p=0.55). Although those experiencing 0 GI AEs appeared to perform slightly better than the other groups, this may be explained by the higher withdrawal rate as the number of GI AE increase. These results were further supported by comparable mean weight loss profiles over time across the 0, 1, 2-3, or ≥4 GI AE groups.
Conclusion: The weight loss observed with liraglutide 3.0 mg is not explained by the occurrence of GI AEs, including nausea/vomiting.

By clicking “Accept Terms & all Cookies” or by continuing to browse, you agree to the storing of third-party cookies on your device to enhance your user experience and agree to the user terms and conditions of this learning management system (LMS).

Cookie Settings
Accept Terms & all Cookies